DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...
Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...
3d
Abzena Recognized as a Market-Leading Antibody-Drug Conjugate CDMO in Frost & Sullivan Radar Report
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the ...
The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced ...
In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer Institute reflects on how antibody-drug conjugates (AD ...
Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...
A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.
Stem CentRx posits that cancer is caused by stem cells gone awry - and is developing antibody drug conjugate therapies to help attack cancer at its root. The Peter Thiel-backed "unicorn" startup is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results